| TRADING CENTER |
| Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EOR... - Business Wire | |
| Geron to Present at LCM Healthcare Conference - Business Wire | |
| Trading Outlook for StemCells Inc. Issued by InvestorSoup.com - GlobeNewswire | |
| Geron Collaborators Publish Data on hESC-Derived Glial Progenitor Cell Therapy in Cer... - Business Wire | |
| 5 Superball Stocks - MotleyFool.com | |
| Geron and FDA Reach Agreement on Clinical Hold - Business Wire | |
| Integrity Media: Stem Cell Report Released - GlobeNewswire | |
| Geron Corporation Reports 2009 Third Quarter Financial Results and Events - Business Wire | |
| Geron Announces Conference Call to Discuss Financial Results for the 2009 Third Quart... - Business Wire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 55.38 | -0.68 / -1.21% | 10.59 |
| GILD | Gilead Sciences Inc | 46.39 | -0.13 / -0.28% | 17.91 |
| CELG | Celgene Corporation | 54.91 | 0.36 / 0.66% | 66.16 |
| 2008 Revenue: | $2.8 M | Headquarters: Menlo Park, CA |
| Employees: | 159 | CEO: Dr. Thomas B. Okarma, Ph.D., M.D. |
| Net Income: | $-62,021,000.0 | Industry: Biotechnology |
| Market Cap: | $511.3 M | Website: www.geron.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| GERN | 5.58 | -0.15 / -2.62% | 5.73 | 5.73 | 5.52 | Profile Chart News |